Anti-LYG1/ SALW1939 functional antibody

Anti-LYG1/ SALW1939 functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to LYG1/LYG1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1085-Ab-1/ GM-Tg-hg-SE1085-Ab-2Anti-Human LYG1 monoclonal antibodyHuman
GM-Tg-rg-SE1085-Ab-1/ GM-Tg-rg-SE1085-Ab-2Anti-Rat LYG1 monoclonal antibodyRat
GM-Tg-mg-SE1085-Ab-1/ GM-Tg-mg-SE1085-Ab-2Anti-Mouse LYG1 monoclonal antibodyMouse
GM-Tg-cynog-SE1085-Ab-1/ GM-Tg-cynog-SE1085-Ab-2Anti-Cynomolgus/ Rhesus macaque LYG1 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1085-Ab-1/ GM-Tg-felg-SE1085-Ab-2Anti-Feline LYG1 monoclonal antibodyFeline
GM-Tg-cang-SE1085-Ab-1/ GM-Tg-cang-SE1085-Ab-2Anti-Canine LYG1 monoclonal antibodyCanine
GM-Tg-bovg-SE1085-Ab-1/ GM-Tg-bovg-SE1085-Ab-2Anti-Bovine LYG1 monoclonal antibodyBovine
GM-Tg-equg-SE1085-Ab-1/ GM-Tg-equg-SE1085-Ab-2Anti-Equine LYG1 monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1085-Ab-1/ GM-Tg-hg-SE1085-Ab-2; GM-Tg-rg-SE1085-Ab-1/ GM-Tg-rg-SE1085-Ab-2;
GM-Tg-mg-SE1085-Ab-1/ GM-Tg-mg-SE1085-Ab-2; GM-Tg-cynog-SE1085-Ab-1/ GM-Tg-cynog-SE1085-Ab-2;
GM-Tg-felg-SE1085-Ab-1/ GM-Tg-felg-SE1085-Ab-2; GM-Tg-cang-SE1085-Ab-1/ GM-Tg-cang-SE1085-Ab-2;
GM-Tg-bovg-SE1085-Ab-1/ GM-Tg-bovg-SE1085-Ab-2; GM-Tg-equg-SE1085-Ab-1/ GM-Tg-equg-SE1085-Ab-2
Products NameAnti-LYG1 monoclonal antibody
Formatmab
Target NameLYG1
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-LYG1 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1085-Ag-1Recombinant multi-species LYG1/ SALW1939 protein
    ORF Viral VectorvGMLP004176human LYG1 Lentivirus particle
    ORF Viral VectorpGMLP004176human LYG1 Lentivirus plasmid
    ORF Viral VectorpGMLPm004696mouse Lyg1 Lentivirus plasmid
    ORF Viral VectorvGMLPm004696mouse Lyg1 Lentivirus particle


    Target information

    Target IDGM-SE1085
    Target NameLYG1
    Gene ID129530,69541,503254,709203,611605,101086644,107132898,100050578
    Gene Symbol and Synonyms2300002O18Rik,LYG1,LYGA1,RGD1560332,SALW1939
    Uniprot AccessionQ8N1E2
    Uniprot Entry NameLYG1_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000144214
    Target ClassificationN/A

    The target: LYG1, gene name: LYG1, also named as SALW1939. Predicted to enable lysozyme activity. Predicted to be involved in defense response to Gram-positive bacterium. Predicted to be active in extracellular region. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.